Today: 7 February 2026
Subscribe
Browse Category

Mergers & Acquisitions News 19 December 2025 - 20 December 2025

Warner Bros. Discovery stock today: Netflix deal vs Paramount $30 bid, analyst forecasts, and what’s next — Dec. 20, 2025

Warner Bros. Discovery stock today: Netflix deal vs Paramount $30 bid, analyst forecasts, and what’s next — Dec. 20, 2025

Warner Bros. Discovery, Inc. stock has turned into a real-time market referendum on one question: which takeover path (if any) actually closes. As of the latest available quote, WBD shares were around $27.77, leaving the stock effectively pinned near Netflix’s agreed $27.75-per-share value while still sitting below Paramount Skydance’s $30 all-cash tender offer. That gap — roughly $2.23 per share, or about 8% upside to Paramount’s headline price — is the market’s way of pricing in deal friction: financing certainty, regulatory timing, and the messy mechanics of a split-up that has to happen before Netflix can consummate its purchase of
20 December 2025
·······
Amicus Therapeutics Stock (FOLD) Surges After $4.8B BioMarin Buyout: $14.50 Offer, Deal Timeline, Analyst Outlook (Dec. 20, 2025)

Amicus Therapeutics Stock (FOLD) Surges After $4.8B BioMarin Buyout: $14.50 Offer, Deal Timeline, Analyst Outlook (Dec. 20, 2025)

Amicus Therapeutics, Inc. (NASDAQ: FOLD) is having the kind of week biotech traders both crave and fear: a sudden, definitive catalyst that snaps the stock to a new reality overnight. On Friday, December 19, shares jumped about 30% and hovered around $14.18, after BioMarin Pharmaceutical announced a $14.50-per-share all-cash acquisition valuing Amicus at roughly $4.8 billion. Reuters+1 Because it’s a cash buyout, the story for Amicus stock is now less about “quarterly beats” and more about a single question: Will the deal close on time and on the stated terms? And that question—plus a few spicy subplots like patent litigation
20 December 2025
·····
Amicus Therapeutics (FOLD) Stock After Hours Dec. 19, 2025: BioMarin’s $14.50 Cash Buyout and What to Know Before the Next Market Open

Amicus Therapeutics (FOLD) Stock After Hours Dec. 19, 2025: BioMarin’s $14.50 Cash Buyout and What to Know Before the Next Market Open

Amicus Therapeutics, Inc. (NASDAQ: FOLD) ended Friday’s session (December 19, 2025) in a very different place than it started: the stock re-priced into “deal mode” after BioMarin Pharmaceutical (NASDAQ: BMRN) announced a definitive agreement to acquire Amicus in an all-cash transaction valued at roughly $4.8 billion. BioMarin Investors+2Reuters+2 With U.S. markets closed on the weekend, the “tomorrow open” investors are thinking about is really the next trading session on Monday, December 22, 2025—and the key question isn’t “growth vs. pipeline” anymore. It’s deal probability vs. deal timeline (and whether a rival bid emerges). SEC+1 What happened to Amicus Therapeutics stock
20 December 2025
····
SPX Technologies (SPXC) Stock News Today: Crawford United Deal, 2025 Guidance Raise, and Fresh Analyst Forecasts (Dec. 19, 2025)

SPX Technologies (SPXC) Stock News Today: Crawford United Deal, 2025 Guidance Raise, and Fresh Analyst Forecasts (Dec. 19, 2025)

SPX Technologies, Inc. (NYSE: SPXC) is having one of those “don’t confuse me with the S&P 500 index” days—because SPX is the index ticker many traders watch, while SPXC is the Charlotte-based engineered-products company riding powerful trends in HVAC and infrastructure equipment. On Friday, December 19, 2025, SPXC shares were volatile and finished lower on the day, even as the stock remains up sharply over the past year and analysts continue to debate how much upside is left after a big multi-year run. StockAnalysis+1 Below is a full, up-to-date breakdown of the latest SPX Technologies stock news, analyst price targets
19 December 2025
····
ABM Industries (ABM) Stock Slides After Earnings: Record 2025 Revenue, WGNSTAR Acquisition, Dividend Hike and 2026 Forecasts (Dec. 19, 2025)

ABM Industries (ABM) Stock Slides After Earnings: Record 2025 Revenue, WGNSTAR Acquisition, Dividend Hike and 2026 Forecasts (Dec. 19, 2025)

ABM Industries Incorporated (NYSE: ABM) is ending the week with investors debating a classic market paradox: record revenue and a bigger dividend on one side, and a sharp earnings miss plus fresh analyst caution on the other. On Friday, December 19, ABM shares traded around $41.78, down about 3.9% on the day, as the market continued to digest the company’s fiscal fourth-quarter report, its $275 million WGNSTAR acquisition agreement, and new Wall Street commentary. What happened to ABM stock this week? ABM’s volatility has been tied to a rapid sequence of headline catalysts: The initial reaction wasn’t uniformly negative. Reuters
19 December 2025
····
Caterpillar Stock (NYSE: CAT) Today: AI-Linked Rally Faces a Reality Check as Analysts Lift Targets and RPMGlobal Deal Advances

Caterpillar Stock (NYSE: CAT) Today: AI-Linked Rally Faces a Reality Check as Analysts Lift Targets and RPMGlobal Deal Advances

December 19, 2025 — Caterpillar, Inc. (NYSE: CAT) is ending the week in the spotlight after a sharp, multi-session pullback collided with fresh analyst target increases and a meaningful step forward in the company’s mining software expansion strategy. At last check on Friday, CAT traded around $576.56, up about 1.9% on the day after Thursday’s close, as broader U.S. equities climbed into year-end trading. Below is what’s driving Caterpillar stock on 19.12.2025, what Wall Street is forecasting for 2026, and what investors are watching next. Caterpillar stock’s volatile week: from record-high momentum to a five-day slide Caterpillar has been a
19 December 2025
·····
ServiceNow (NOW) Stock Today: Post-Split Trading, Armis Deal Talk, Analyst Targets, and What Wall Street Is Watching on Dec. 19, 2025

ServiceNow (NOW) Stock Today: Post-Split Trading, Armis Deal Talk, Analyst Targets, and What Wall Street Is Watching on Dec. 19, 2025

ServiceNow, Inc. (NYSE: NOW) is back in the spotlight on December 19, 2025—this time for a mix of market mechanics and strategy that rarely collide so loudly in a single week: a fresh 5-for-1 stock split, unusually sharp volatility tied to blockbuster M&A rumors, and a renewed debate about how quickly enterprise software leaders can turn “agentic AI” into real, recurring dollars. As of the latest available quote on Dec. 19, ServiceNow shares were trading around $155, after opening near $154 and moving in a roughly $153–$157 intraday range. That price action comes as U.S. equities broadly climbed on Friday
19 December 2025
····
DJT Stock News Today: Trump Media Shares Jump Again on Dec. 19 as $6 Billion TAE Fusion Merger Sparks Fresh Volatility

DJT Stock News Today: Trump Media Shares Jump Again on Dec. 19 as $6 Billion TAE Fusion Merger Sparks Fresh Volatility

Dec. 19, 2025 — Trump Media & Technology Group Corp. (NASDAQ: DJT) is trading sharply higher again on Friday, extending a stunning two-day move after the Truth Social parent announced an all-stock merger with nuclear fusion company TAE Technologies—a pivot that has Wall Street, retail traders, and policy watchers parsing the fine print in real time. Reuters The rally comes with a familiar DJT signature: heavy volume, fast price swings, and a debate that’s less about near-term earnings and more about narrative—this time, the idea that fusion energy could become a critical power source for the AI boom. Barron’s+1 DJT
19 December 2025
···
Warner Bros. Discovery (WBD) Stock News Today: Harris Associates Signals Openness to a Higher Paramount Bid as Netflix Deal Terms Stay in Focus (Dec. 19, 2025)

Warner Bros. Discovery (WBD) Stock News Today: Harris Associates Signals Openness to a Higher Paramount Bid as Netflix Deal Terms Stay in Focus (Dec. 19, 2025)

Warner Bros. Discovery, Inc. Series A (NASDAQ: WBD) is trading like a live market referendum on one question: does the Netflix agreement hold—or does Paramount Skydance come back with a cleaner, higher, and more financeable offer? On December 19, 2025, WBD shares traded around $28.15, after opening near $27.80 and moving in an intraday range of roughly $27.60 to $28.445, underscoring how tightly the stock is tethered to deal headlines and merger-arbitrage expectations. The day’s most market-moving update: Harris Associates—described as WBD’s fifth-largest shareholder—said it would be “very open” to a revised Paramount Skydance bid if Paramount improves the economics
19 December 2025
·······
Robinhood Stock News Today (Dec. 19, 2025): HOOD Rises as Analysts Tout a Prediction-Markets “Supercycle” and WonderFi Deal Timeline Extends

Robinhood Stock News Today (Dec. 19, 2025): HOOD Rises as Analysts Tout a Prediction-Markets “Supercycle” and WonderFi Deal Timeline Extends

Robinhood Markets, Inc. (NASDAQ: HOOD) stock traded higher on Friday, December 19, 2025, as investors digested a fresh corporate update tied to Robinhood’s international crypto expansion and a steady drumbeat of bullish Wall Street commentary around the company’s fast-growing “prediction markets” business. As of 15:14 UTC on Dec. 19, Robinhood shares were at $121.16, up $4.00 (+3.41%) on the day, after trading between $118.23 and $121.43 with volume around 6.0 million shares. HOOD’s market capitalization at that time was approximately $127.2 billion. That move caps a week in which Robinhood has remained tightly linked to two narratives: (1) the industry-wide
19 December 2025
······
BioMarin to Acquire Amicus Therapeutics for $4.8 Billion in All‑Cash Deal, Expanding Rare Disease Drug Portfolio

BioMarin to Acquire Amicus Therapeutics for $4.8 Billion in All‑Cash Deal, Expanding Rare Disease Drug Portfolio

BioMarin Pharmaceutical is set to deepen its push into rare metabolic diseases after announcing a definitive agreement to acquire Amicus Therapeutics in an all‑cash transaction valued at approximately $4.8 billion. The deal would add two marketed therapies—Galafold for Fabry disease and Pombiliti + Opfolda for Pompe disease—while also bringing in a Phase 3 kidney-disease program that could widen BioMarin’s late‑stage pipeline. BioMarin Corporate+1 The acquisition is the latest example of a larger biotech company using M&A to secure near‑term revenue and strengthen long‑term growth, particularly in rare disease categories where commercialization requires specialized manufacturing, reimbursement know‑how, and tight engagement with
19 December 2025
····
DJT Stock Surges After Trump Media’s $6 Billion TAE Fusion Merger Plan: Price, Deal Terms, and 2026–2031 Outlook (Dec. 19, 2025)

DJT Stock Surges After Trump Media’s $6 Billion TAE Fusion Merger Plan: Price, Deal Terms, and 2026–2031 Outlook (Dec. 19, 2025)

Trump Media & Technology Group Corp. (ticker: DJT) is back in the center of the market’s attention on December 19, 2025, after a headline-grabbing pivot that sent shares sharply higher: the Truth Social parent said it has signed a definitive all-stock merger agreement with TAE Technologies, a Google-backed nuclear fusion company, in a transaction the companies value at more than $6 billion. SEC+1 The announcement instantly re-framed “DJT stock” from a social-media-and-fintech story into an “AI power infrastructure” storyline—one that’s colliding with today’s urgent debate over how the U.S. can feed electricity-hungry data centers without breaking the grid. Below is
19 December 2025
····
1 … 5 6 7 8 9 … 34

Stock Market Today

Nvidia stock jumps nearly 8% as Big Tech AI spending bets lift chipmakers and Dow tops 50,000

Nvidia stock jumps nearly 8% as Big Tech AI spending bets lift chipmakers and Dow tops 50,000

7 February 2026
Nvidia surged 7.8% Friday, leading a chip stock rally that pushed the Dow above 50,000 for the first time. The PHLX semiconductor index gained 5.7% as Advanced Micro Devices rose 8.3% and Broadcom 7.1%. Amazon fell 5.6% after projecting $200 billion in 2026 capital spending. Investors weighed a $600 billion AI infrastructure outlay against sharp losses in software shares.
Glencore share price steadies after Rio Tinto walks away — what to watch next week

Glencore share price steadies after Rio Tinto walks away — what to watch next week

7 February 2026
Glencore shares closed up 0.6% at 478.1 pence Friday, rebounding after a 7% drop following the collapse of merger talks with Rio Tinto. The company is expected to announce the sale of its Kazzinc stake soon and has signed a non-binding agreement with Orion for a potential $9 billion deal in the DRC. Investors await Glencore’s full-year results on Feb. 18 for further guidance.
Go toTop